Lung transplant rejection – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:34:55 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Lung transplant rejection – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety of Allogeneic Mesenchymal Stromal Cells for Patients with Chronic Lung Transplant Rejection https://clinicaltrials.eu/trial/study-on-the-safety-of-allogeneic-mesenchymal-stromal-cells-for-patients-with-chronic-lung-transplant-rejection/ Wed, 29 Apr 2026 14:57:50 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-of-allogeneic-mesenchymal-stromal-cells-for-patients-with-chronic-lung-transplant-rejection/ This clinical trial is focused on studying a condition known as chronic lung transplant rejection, which can occur in patients who have received a lung transplant. The study is investigating a treatment using a special type of cells called allogeneic mesenchymal stromal cells. These cells are derived from bone marrow and are expanded outside the body before being used. The treatment involves administering these cells directly into the lungs through a procedure called endobronchial administration.

The main purpose of the study is to assess the safety of this cell-based treatment in patients who have experienced chronic rejection after a lung transplant. Participants in the study will receive either the cell treatment or a placebo. The study will monitor participants for any side effects or adverse reactions, such as changes in breathing or infections, following the administration of the cells. The study will also track the progression of the lung condition over time.

Participants will be followed for a period of time to observe any changes in their lung function and overall health. The study aims to provide valuable information on whether this new treatment can help manage chronic lung transplant rejection safely. The results could potentially lead to new treatment options for patients experiencing this challenging condition.

]]> Study on the Effectiveness of Belumosudil and Azithromycin for Adults with Chronic Lung Rejection After Lung Transplant https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-belumosudil-and-azithromycin-for-adults-with-chronic-lung-rejection-after-lung-transplant/ Wed, 29 Apr 2026 14:26:35 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-belumosudil-and-azithromycin-for-adults-with-chronic-lung-rejection-after-lung-transplant/ This clinical trial is focused on studying a condition known as chronic lung allograft dysfunction (CLAD), which can occur after a person has received a lung transplant. The study is testing a treatment called belumosudil, which is taken as a tablet. The purpose of the study is to evaluate how effective belumosudil is in improving lung function in adults who have developed CLAD after a lung transplant. Participants in the study will be randomly assigned to receive either belumosudil or a placebo, which is a tablet that looks like the treatment but does not contain the active medicine.

During the study, participants will take the tablets by mouth. The study will be conducted in two parts: an initial phase where participants will not know if they are receiving belumosudil or the placebo, followed by an open-label phase where all participants will receive belumosudil. The study will last for several months, and participants will have regular check-ups to monitor their lung function and overall health. Lung function will be measured using a test called forced expiratory volume in 1 second (FEV1), which assesses how much air a person can exhale in one second.

Participants in the study will have already been treated with another medication called azithromycin for at least eight weeks before starting the trial. The study aims to see if belumosudil can help improve lung function and slow down the progression of CLAD. Throughout the study, researchers will also monitor for any side effects or adverse events to ensure the safety of the participants. The results of this study could provide valuable information about the potential benefits of belumosudil for people with CLAD following a lung transplant.

]]>